Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml Publisher Pubmed



Mahalleh M1 ; Shabani M1, 2, 3 ; Rayzan E1, 2 ; Rezaei N2, 3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. International Hematology/Oncology of Pediatrics Experts (IHOPE), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  2. 2. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Immunotherapy Published:2019


Abstract

Recent therapeutic advances in cancer treatment recruit immune system potentiation against malignant cells. Numerous ongoing clinical trials on immunotherapy methods, either monotherapy or combination therapy, are investigating the impeding factors on the way of acute myeloid leukemia (AML) treatment. Due to the genetic diversity in AML progenitors, combining various strategies is more likely to be useful for improving patient outcomes. This review describes the details of applying monoclonal antibodies against AML, focusing on CD33, CD123, FLT3, CD45 and CD66 targeting. Furthermore, it clarifies the importance of immunotoxins, bispecific antibodies, chimeric antigen receptor (CAR)-T cells and T cell receptor-modified cells as reinforcing agents for monoclonal antibodies. © 2019 © 2019 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
2. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)
3. Immunotherapy in Aml: A Brief Review on Emerging Strategies, Clinical and Translational Oncology (2021)
4. Investigation of Cebpa and Cebpa-As Genes Expression in Acute Myeloid Leukemia, Reports of Biochemistry and Molecular Biology (2019)
5. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)
6. Mutational Screening of Rtk-Braf Genes in De Novo Adult Acute Myeloid Leukemia, Gene Reports (2020)
7. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
8. Genetic, Hematologic and Psychological Aspects of Leukemia, Cancer Genetics and Psychotherapy (2017)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (8)
Saeed Mohammadi (2)
Other Related Docs
9. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
10. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
11. Dendritic Cell Vaccination Strategy for the Treatment of Acute Myeloid Leukemia: A Systematic Review, Cytotherapy (2024)
12. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
13. Toll-Like Receptor 4 Signaling Pathway Is Correlated With Pathophysiological Characteristics of Aml Patients and Its Inhibition Using Tak-242 Suppresses Aml Cell Proliferation, International Immunopharmacology (2021)
14. Parthenolide: Pioneering New Frontiers in Hematological Malignancies, Frontiers in Pharmacology (2025)
15. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)
16. Covid-19 Pathology on Various Organs and Regenerative Medicine and Stem Cell-Based Interventions, Frontiers in Cell and Developmental Biology (2021)
17. Signaling Pathways Governing the Behaviors of Leukemia Stem Cells, Genes and Diseases (2024)
18. Studying the Potential of Upregulated Ptgs2 and Vegf-C Besides Hyper-Methylation of Ptgs2 Promoter As Biomarkers of Acute Myeloid Leukemia, Molecular Biology Reports (2022)
19. Inducing Apoptosis in Acute Myeloid Leukemia; Mechanisms and Limitations, Heliyon (2025)
20. Production of Car T-Cells by Gmp-Grade Lentiviral Vectors: Latest Advances and Future Prospects, Critical Reviews in Clinical Laboratory Sciences (2019)
21. Fundamental Concepts of Protein Therapeutics and Spacing in Oncology: An Updated Comprehensive Review, Medical Oncology (2023)
22. Update on Immune-Based Therapy Strategies Targeting Cancer Stem Cells, Cancer Medicine (2023)
23. Immunopathology and Immunotherapy of Myeloid Leukemia, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
24. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
25. Transplantation, Clinical Immunology (2022)
26. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
27. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
28. Advances in Immunotoxin Engineering: Precision Therapeutic Strategies in Modern Oncology, Medical Oncology (2024)
29. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
30. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
31. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
32. Investigation of the Osteopontin Isoforms Expression in Patients With Acute Myeloid Leukemia, Medical Oncology (2021)
33. The Gene Expression Profile and Dna Methylation Pattern of Cdh1 and Dnmt1 Genes in Acute Promyelocytic Leukemia (Apl), Reports of Biochemistry and Molecular Biology (2020)
34. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)